Rudolf Despina, Silberzahn Tobias, Walter Steffen, Maurer Dominik, Engelhard Johanna, Wernet Dorothee, Bühring Hans-Jörg, Jung Gundram, Kwon Byoung S, Rammensee Hans-Georg, Stevanović Stefan
Department of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany.
Cancer Immunol Immunother. 2008 Feb;57(2):175-83. doi: 10.1007/s00262-007-0360-x. Epub 2007 Jul 27.
The in vitro generation of cytotoxic T lymphocytes (CTLs) for anticancer immunotherapy is a promising approach to take patient-specific therapy from the bench to the bedside. Two criteria must be met by protocols for the expansion of CTLs: high yield of functional cells and suitability for good manufacturing practice (GMP). The antigen presenting cells (APCs) used to expand the CTLs are the key to achieving both targets but they pose a challenge: Unspecific stimulation is not feasible because only memory T cells are expanded and not rare naïve CTL precursors; in addition, antigen-specific stimulation by cell-based APCs is cumbersome and problematic in a clinical setting. However, synthetic artificial APCs which can be loaded reproducibly with MHC-peptide monomers and antibodies specific for costimulatory molecules could resolve these problems. The purpose of this study was to investigate the potential of complex synthetic artificial APCs in triggering the costimulatory molecules CD28 and 4-1BB on the T cell. Anti-4-1BB antibodies were added to an established system of microbeads coated with MHC-peptide monomers and anti-CD28. Triggering via CD28 and 4-1BB resulted in strong costimulatory synergy. The quantitative ratio between these signals determined the outcome of the stimulation with optimal results when anti-4-1BB and anti-CD28 were applied in a 3:1 ratio. Functional CTLs of an effector memory subtype (CD45RA(-) CCR7(-)) were generated in high numbers. We present a highly defined APC platform using off-the-shelf reagents for the convenient generation of large numbers of antigen-specific CTLs.
通过体外生成细胞毒性T淋巴细胞(CTL)进行抗癌免疫治疗是一种很有前景的方法,有望将针对患者的特异性治疗从实验室应用到临床。CTL扩增方案必须满足两个标准:高产量的功能性细胞以及符合良好生产规范(GMP)。用于扩增CTL的抗原呈递细胞(APC)是实现这两个目标的关键,但它们也带来了挑战:非特异性刺激不可行,因为只能扩增记忆T细胞,而不是罕见的初始CTL前体;此外,在临床环境中,基于细胞的APC进行抗原特异性刺激既麻烦又存在问题。然而,能够可重复加载MHC-肽单体和共刺激分子特异性抗体的合成人工APC可以解决这些问题。本研究的目的是探讨复杂合成人工APC在触发T细胞上共刺激分子CD28和4-1BB方面的潜力。将抗4-1BB抗体添加到已建立的涂有MHC-肽单体和抗CD28的微珠系统中。通过CD28和4-1BB触发产生了强烈的共刺激协同作用。这些信号之间的定量比例决定了刺激的结果,当抗4-1BB和抗CD28以3:1的比例应用时效果最佳。大量产生了效应记忆亚型(CD45RA(-) CCR7(-))的功能性CTL。我们展示了一个高度明确的APC平台,使用现成的试剂方便地大量生成抗原特异性CTL。